The consensus for diagnosis and treatment of multiple myeloma-related bone disease

Title: The consensus for diagnosis and treatment of multiple myeloma-related bone disease
Edition: Adapted
Classification: Experts consensus
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: The hematologist.
Evidence classification method: GRADE
Development unit: Beijing Jishuitan Hospital
Registration time: 2023-05-26
Registration number: PREPARE-2023CN367
Purpose of the guideline: Multiple myeloma-related bone disease (MBD) is an important complication that runs through the entire course of multiple myeloma. The diagnosis, treatment, and curative effect evaluation of MBD involve multidisciplinary collaborations including hematology, radiology, bone oncology, radiotherapy, and rehabilitation medicine. The previous guidelines for diagnosing and treating MBD were all written by hematologists, with little involvement in imaging examination and surgical treatment. Therefore, the formulation of this expert consensus invited many experts including the above-mentioned multidisciplinary to co-author, aiming to guide the multidisciplinary diagnosis and treatment of MBD, standardize the multidisciplinary diagnosis and treatment of myeloma bone disease, and improve the multiple treatment efficacy and quality of life in patients with myeloma.